Tue, Sep 16, 2014, 9:01 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

IntelliCell BioSciences, Inc. Message Board

annickawaechter 235 posts  |  Last Activity: 3 hours ago Member since: Mar 28, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • annickawaechter by annickawaechter Aug 13, 2014 3:39 PM Flag

    Most of the longs own this stock for at least several months, hoping for FDA approval and assured of the company's potential after last quarter's positive net income, reimbursement in France and recommendation by the European association of urologists for low and mid risk prostate cancer treatment. That means most of the longs are in this stock at a share price of 2.80 dollar/share-5.80 dollar/share.
    If Q2 gives another positive eps and net income, longs will stay long and won't think a second on selling under their entry price, meaning that 2.80 dollar/share will be the ultimate bottom.
    With only 25 million shares outstanding and an average trading volume around 600.000 shares/day it will become very difficult for shorts to cover, meaning that they will neeeeeeeeeeeeed day traders to get rid of their short position.
    So if Q2 gives a positive EPS, with no additional positive news, please do expect a minimum share price of $2.80

    Sentiment: Strong Buy

  • Marc Oczachowski, EDAP's Chief Executive Officer, stated, "We are very enthusiastic about the Company's all time record results for the first quarter driven by a growing demand for our HIFU devices. This reflects the strong market momentum for our new Focal One HIFU technology that was introduced in Europe last summer. It is very exciting to see the growing adoption of our products among the urology community as we now have a complete and unique HIFU offering including Focal One and Ablatherm to cover most market needs. As we advance through the second quarter, we have a strong sales backlog featuring ten lithotripters and two HIFU devices and remain focused on driving product sales."

    Sentiment: Strong Buy

  • The FDA sets a PDUFA, where the final decision falls, this is not the case now.... Why? Still in discussions, so FDA really doubts if they should follow their panels' advice or therecommendation of the Euopean association of urologists.

    Sentiment: Strong Buy

  • Reply to

    The financial picture looks good

    by annickawaechter Sep 13, 2014 4:03 AM
    annickawaechter annickawaechter Sep 13, 2014 4:04 AM Flag

    Now that they have orphan drug status for Pertussis the company does not have to pay FDA fees. Also good for their financials.

    Sentiment: Strong Buy

  • Reply to

    share price

    by vinhhoixuan2000 Aug 13, 2014 1:51 PM
    annickawaechter annickawaechter Aug 13, 2014 2:25 PM Flag

    Reimbursement news from other European countries
    Decision in China
    ...

    Sentiment: Strong Buy

  • annickawaechter by annickawaechter Jun 18, 2014 2:09 PM Flag

    1. Another approval for reimbursement in Europe after France.
    2. Partnership announcement in the US, be aware this is a European company so a partnership in the US makes sense.
    3. The announcement for a medical trial to evaluate the possibility to treat other types of cancers besides prostate cancer
    4. Buyout

    Sentiment: Strong Buy

  • Reply to

    summary from shorties bashing attempts

    by alexander.johannes Aug 12, 2014 2:57 PM
    annickawaechter annickawaechter Aug 13, 2014 2:03 AM Flag

    7. If the company had good numbers they would pre-announce them: well, in fact they already pre-announced them at the comment on their financial Q1 saying they already had a strong backlog for Q2 and that France has started reimbursing at end of Q1. 28 August is a normal date because last year they released their number on August 24.
    8. Wow so many lawsuits: well, there can be a million lawsuits, the company is insured and there is no fraud.

    Sentiment: Strong Buy

  • annickawaechter by annickawaechter Aug 28, 2014 12:32 PM Flag

    And won't sell a single share under $20/share.

    Hifu is now in trials for brain cancer as well (look at the linkedin page of EDAP), that should be an indication fortheir focal one device. They have incredible opportunities:
    Kidney cancer, liver metastasis, pancreatic cancer and now brain cancer as well.

    They can get reimbursement in other European countries,get approval inChina and Japan, get FDA approval,...

    And they have no senior debts and 17,5 million dollar in cash

    Sentiment: Strong Buy

  • annickawaechter by annickawaechter Sep 13, 2014 4:03 AM Flag

    Financial picture. Last year they raised about 12million through sale of stock. They are burning about 12 million per year average last 4 years. As of June 30, 2014 they had 8 million cash with just over 1 million liabilities. The 89million is carry forward losses not debt.

    Sentiment: Strong Buy

  • Reply to

    The financial picture looks good

    by annickawaechter Sep 13, 2014 4:03 AM
    annickawaechter annickawaechter Sep 13, 2014 4:14 AM Flag

    With these excellent Trimesta results the company does not needa large phase 3 population to statistically meet primary and secondary endpoints nor conform safety. Trial could be done in 1 year with these results, so it won't cost that much. That is why the company is considering the option to do the trial without partner.

    Sentiment: Strong Buy

  • Reply to

    FDA can Reverse decision of AdCom

    by hcri50 Aug 10, 2014 3:53 PM
    annickawaechter annickawaechter Aug 10, 2014 4:06 PM Flag

    Robert, I fully agree that there is a chance the FDA will change adcomms' vote. Wouldn't they make themselves very ridiculous when they neglect 40.000 successfull treatments over Canada, Europe, Russia, parts of Asia and South America?! Wouldn't they make themselves ridiculous when their colleagues from the European association of urologists recommend Ablatherm for the first-in-line and salvage treatment for low tot mid-risk prostate cancer treatment (and France goes even further by reimbursing the treatment)?! But Robert, EDAP is not testing Ablatherm for breast cancer, but for liver metastasis and pancreatic cancer. Urologists would love to use it for kidney cancer as well, but I have no idea the company is currently doing trials on kidney cancer. PS China decision is before the end of this year (IR told me that over the phone)

    Sentiment: Strong Buy

  • annickawaechter annickawaechter Aug 9, 2014 9:43 AM Flag

    Per IR, I called them Wednesday and Friday and will call again on Monday to talk with the CFO, decision in China comes before the end of this year.

    Sentiment: Strong Buy

  • annickawaechter annickawaechter Aug 18, 2014 6:44 AM Flag

    Which won't be any problem:
    Mr. Oczachowski continued, "Our HIFU technology has now gained a new status among the international urology community and health authorities. Just last month, France's Ministry of Health granted national reimbursement for prostate cancer treatment procedures using HIFU and the European Association of Urology updated its guidelines to recommend HIFU as primary and salvage prostate cancer therapy.

    Sentiment: Strong Buy

  • annickawaechter by annickawaechter Aug 29, 2014 2:24 PM Flag

    pipeline:
    1. pancreatic cancer and liver metastasis, kidney cancer and in the future brain cancer; some say breast cancer as well but I have no info about that

    2. a new device is coming: read the cc transcript, almost every year they have a new device, or update from a device out, so I expect to see news in the comings months about this

    3. if they succeed to partner for US and Asia sales, I expect edap will take over an other company or do a share buy back

    milestones:
    1. reimbursement news from other European countries
    2.recommendation from Europe to upgrade salvage treatment to "B" and make a recommendation for high risk prostate cancer too
    3. decision in China and Japan
    4. FDA decision
    5. update from pancreatic and liver trials
    6. ...

    Sentiment: Strong Buy

  • 1. Big analyst firms give OREX a target of $10/share or higher on FDA approval. Don't tell me their analysts haven't studied the obesity market and near future competition before placing their price target.
    2. The typical bear raid before FDA approval was very light. Shorts are #$%$ and nervous, because they did expect a greater downfall.
    3. The Takeda agreement has been strengthened
    4. They just increased their patent portfolio in the diabetes market
    5. FDA approval will increase mid term speculation for EU approval in a couple of months

    I think the share price will spike +100%

    Sentiment: Strong Buy

  • That is the difference. It will become first in its' class for the treatment of multiple sclerosis.
    With this data published in a scientific journal, SYN should be valued 10x more than today.

    And then I am not talking yet about other applications of Trimesta e.g. on Alzheimer

    Sentiment: Strong Buy

  • annickawaechter by annickawaechter Jul 15, 2014 3:19 PM Flag

    "Hi
    I hope some of you find this information helpful. i used a world renown urologist dr van Velthoven, he's the head urologist at the Jules Bordet (cancer specific hospital) in Brussels, Belgium. He has over 10 year experience and has been published in over 75 journals for his work. He also was the head of the Belgian urology association and has an impressive resume. He's also considerably less expensive than other HIFU experts because the hospital is a public hospital as opposed to a private clinic in Canada for $13,500 I got:

    Medication
    Doctors fees and consultation
    Pathology report
    Anesthesia
    follow up via email from nurses and urologist
    preoperative examination and testing (MRI, EKG etc)
    HIFU or High Intensity Focused Ultrasound treatment

    I had to book my treatment (because it was international) through a company called Alternatives, the full name is alternative prostate cancer care they are in Calgary alberta but book for the hifu hospital in belgium. i was very impressed and they sent me a ton of other info on the doctor and long term studies. I also got a free consultation from the doctor prior to going and was able to talk over my fears with him. The company also arranged for medical travel insurance.

    Sentiment: Strong Buy

  • Reply to

    concerns about edap

    by netcurrentassetvalue Aug 10, 2014 7:28 AM
    annickawaechter annickawaechter Aug 10, 2014 7:39 AM Flag

    Good points. What I expect is that earnings will continue to rise due to reimbursement in France. As recommended for low and mid risk lokalized prostate cancer treatment by the European association of urologists, I expect positive reimbursement news in other European countries like Belgium, the Netherlands, Spain in the first place (tigenix a small belgian biotech stem cell company, whose main product was FDA denied got reimbursement in these countries too, on a very quick pace once the first reimbursement was a fact. They got 18million dollars in cash and net come, that will be sufficient to continue ongoing for pancreatic cancer and liver metastasis. On the long term my target is $50/share

    Sentiment: Strong Buy

  • Wouldn't you feel extremely humiliated by the vote of your fellow adcomm members, especially when they voted the device was unsafe. All your colleagues from over the world, use the device and then adcomm says "hey, this is not safe". If you were a US urologist, would you dare to come to the next international symposium? I wouldn't dare, because I would fear I would be laughed out in my face and wouldn't longer be respected as a key opinion leader. The entire urology, oncology and medical community is now laughing, no longer respecting the FDA. In my opinion, the FDA has more to lose than EDAP (EDAP is already profitable without the US). The. FDA is about to lose respect and authority in the field of oncology. Therefore, the FDA needs to find a solution. I do not think this is over yet. Strong buy

    Sentiment: Strong Buy

  • annickawaechter annickawaechter Aug 18, 2014 6:42 AM Flag

    Total revenue for the HIFU division was EUR 3.3 million (USD 4.5 million) for the first quarter 2014, compared to EUR 1.4 million (USD 1.8 million) for the same period last year. Results for the first quarter 2014 included the sale of three Ablatherm and two Focal One devices.

    For the three months ended March 31, 2014, total revenue for the lithotripsy division was EUR 4.5 million (USD 6.1 million), in line with EUR 4.5 million (USD 6.0 million), during the year ago period. During the first quarter 2014, the Company recorded sales of nine lithotripsy machines, comprised of seven Sonolith i-move devices, one Sonolith i-sys device, and one Sonolith Praktis, compared to a total of ten devices sold in the first quarter of 2013.

    Sentiment: Strong Buy

SVFC
0.00130.0000(0.00%)Sep 16 3:57 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.